Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma

NCT04541017 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04541017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Terminated
Start date
April 6, 2021
Completion date
October 24, 2024
Enrollment
8 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

mycosis fungoides, recurrent mycosis fungoides, recurrent mycosis fungoides and sezary syndrome, recurrent sezary syndrome, refractory mycosis fungoides, refractory mycosis fungoides and sezary syndrome, refractory sezary syndrome, sezary syndrome, stage ib mycosis fungoides and sezary syndrome ajcc v8, stage ii mycosis fungoides and sezary syndrome ajcc v8, stage iii mycosis fungoides and sezary syndrome ajcc v8, stage iv mycosis fungoides and sezary syndrome ajcc v8